SQZ Biotech, a Watertown, Massachusetts-based preclinical stage biotechnology company, received an investment of undisclosed amount from the JDRF T1D Fund.
With the investment, the T1D Fund also provides the expertise of JDRF, the global organization funding T1D research and accelerating innovations to cure, prevent and treat T1D and its complications.
The company intends to use the funds for the development of its novel therapy for type 1 diabetes (T1D) aimed at retraining the immune system to not attack insulin-producing beta cells.
Led by Bruce Beutel, PhD, Chief Business Officer, SQZ is using its proprietary (CellSqueeze®) technology to develop a series of cell therapy programs to induce immunological tolerance and treat multiple diseases.
In SQZ’s tolerance program, including its new T1D program, auto-antigens are delivered to cells in a way that leverages naturally occurring biological processes to tolerize the patient’s immune system and potentially eliminate its ability to attack healthy tissue.